HIGHLIGHTS
- who: Jinghong Chen from the Sun Yat-sen University Cancer Center TADs have published the research: Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK/T-cell lymphoma to chidamide, in the Journal: (JOURNAL) of 25/08/2016
- what: The authors evaluated the therapeutic effects of chidamide in 28 relapsed/refractory NKTL patients, and a remarkable ORR of 39% was achieved. The authors conducted the first focused trial of chidamide, an oral HDAC inhibitor, in relapsed/refractory NKTL. The study shows that hyperactivation of JAK-STAT signaling confers resistance to chidamide in . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.